Abstract
Objective and method:
To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India.
Results:
Paromomycin is the cheapest option ($7450 to treat 1000 patients). Treating 1000 patients with oral miltefosine would cost $119,250 at the current private market price or $64,383-$75,129 at preferential public sector price depending on the size of the order. With AmBisome it would be $163,600 or $229,500 depending on the dose (10 or 15 mg/kg total). These costs are without considering other direct costs (daily intramuscular injections for 3 weeks for paromomycin; intravenous devices and hospitalization for AmBisome; directly observed treatment if applied for miltefosine) and indirect costs.
Conclusion:
These calculations provide useful basic information for projections.
MeSH terms
-
Adolescent
-
Adult
-
Age Distribution
-
Aged
-
Amphotericin B / administration & dosage
-
Amphotericin B / economics
-
Amphotericin B / therapeutic use
-
Anthropometry / methods
-
Antiprotozoal Agents / administration & dosage*
-
Antiprotozoal Agents / economics
-
Antiprotozoal Agents / therapeutic use
-
Body Weight
-
Child
-
Child, Preschool
-
Dose-Response Relationship, Drug
-
Drug Costs / statistics & numerical data
-
Female
-
Humans
-
India
-
Infant
-
Leishmaniasis, Visceral / drug therapy*
-
Leishmaniasis, Visceral / economics
-
Liposomes
-
Male
-
Middle Aged
-
Paromomycin / administration & dosage
-
Paromomycin / economics
-
Paromomycin / therapeutic use
-
Phosphorylcholine / administration & dosage
-
Phosphorylcholine / analogs & derivatives
-
Phosphorylcholine / economics
-
Phosphorylcholine / therapeutic use
-
Sex Distribution
Substances
-
Antiprotozoal Agents
-
Liposomes
-
liposomal amphotericin B
-
Phosphorylcholine
-
miltefosine
-
Paromomycin
-
Amphotericin B